Bonus Biogroup Ltd
TASE:BONS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bonus Biogroup Ltd
Income from Continuing Operations
Bonus Biogroup Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Income from Continuing Operations
-₪24.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-6%
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Income from Continuing Operations
$20.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Income from Continuing Operations
$1.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Income from Continuing Operations
-$153.5m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Income from Continuing Operations
-$11.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Income from Continuing Operations
-$27.1m
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-2%
|
|
Bonus Biogroup Ltd
Glance View
Bonus Biogroup Ltd. is a biotechnology company engaging in the field of stem cells and tissue engineering. The firm is developing cell therapy products based on autologous and allogeneic bone implants that will enable efficient bone transplant and provide cellular-based bone replacement prosthetics for repairing bone lesions. The company is targeting a worldwide market for the treatment of major disorders such as bone and cartilage related arthritis, osteoporosis, and various types of bones and joint trauma such as hip fractures and knee injuries, among others. On April 29, 2012, Bonus Bio Group Ltd fully acquired Bonus Therapeutic Ltd.
See Also
What is Bonus Biogroup Ltd's Income from Continuing Operations?
Income from Continuing Operations
-24.5m
ILS
Based on the financial report for Dec 31, 2025, Bonus Biogroup Ltd's Income from Continuing Operations amounts to -24.5m ILS.
What is Bonus Biogroup Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-6%
Over the last year, the Income from Continuing Operations growth was 12%. The average annual Income from Continuing Operations growth rates for Bonus Biogroup Ltd have been 14% over the past three years , -2% over the past five years , and -6% over the past ten years .
